Mereo BioPharma Group plc (MAH0) - Total Liabilities
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has total liabilities worth €5.00 Million EUR (≈ $5.85 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mereo BioPharma Group plc - Total Liabilities Trend (2016–2025)
This chart illustrates how Mereo BioPharma Group plc's total liabilities have evolved over time, based on quarterly financial data. See Mereo BioPharma Group plc (MAH0) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Mereo BioPharma Group plc Competitors by Total Liabilities
The table below lists competitors of Mereo BioPharma Group plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Logindo Samudramakmur Tbk
JK:LEAD
|
Indonesia | Rp1.01 Trillion |
|
Carbon Streaming Corp
NEO:NETZ
|
Canada | CA$1.99 Million |
|
Fridenson
TA:FRDN
|
Israel | ILA185.56 Million |
|
Clean TEQ Water Ltd
AU:CNQ
|
Australia | AU$7.72 Million |
|
Unisync Corp
TO:UNI
|
Canada | CA$70.89 Million |
|
Dcon Products Public Company Limited
BK:DCON
|
Thailand | ฿1.10 Billion |
|
TDb Split Corp
TO:XTD
|
Canada | CA$47.56 Million |
|
Beamtree Holdings Ltd
AU:BMT
|
Australia | AU$13.76 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Mereo BioPharma Group plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MAH0 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mereo BioPharma Group plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mereo BioPharma Group plc (2016–2025)
The table below shows the annual total liabilities of Mereo BioPharma Group plc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.00 Million ≈ $5.85 Million |
-67.57% |
| 2024-12-31 | €15.42 Million ≈ $18.03 Million |
-3.39% |
| 2023-12-31 | €15.96 Million ≈ $18.66 Million |
-39.10% |
| 2022-12-31 | €26.21 Million ≈ $30.64 Million |
-31.77% |
| 2021-12-31 | €38.41 Million ≈ $44.91 Million |
-50.70% |
| 2020-12-31 | €77.92 Million ≈ $91.09 Million |
+68.68% |
| 2019-12-31 | €46.19 Million ≈ $54.00 Million |
+33.87% |
| 2018-12-31 | €34.51 Million ≈ $40.34 Million |
+1.93% |
| 2017-12-31 | €33.85 Million ≈ $39.58 Million |
+350.87% |
| 2016-12-31 | €7.51 Million ≈ $8.78 Million |
-- |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung dise… Read more